Literatur
-
1
Hall I C, O’Toole E.
Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis.
Am J Dis Child.
1935;
49
390-402
-
2
Bartlett J G, Chang T W, Gurwith M.
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.
N Engl J Med.
1978;
298
531-534
-
3
Chang V T, Nelson K.
The role of physical proximity in nosocomial diarrhea.
Clin Infect Dis.
2000;
31
717-722
-
4
Kyne L, Sougioultzis S, McFarland L V, Kelly C P.
Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea.
Infect Control Hosp Epidemiol.
2002;
23
653-659
-
5
Pépin J, Saheb N, Coulombe M A. et al .
Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.
Clin Infect Dis.
2005;
41
1254-1260
-
6
Raveh D, Rabinowitz B, Breuer G S. et al .
Risk factors for Clostridium difficile toxin-positive nosocomial diarrhoea.
Int J Antimicrob Agents.
2006;
28
231-237
-
7
Dial S, Kezouh A, Dascal A. et al .
Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection.
Can Med Assoc J.
2008;
178
767-772
-
8
Bauer M P, van Dissel J T, Kuijper E J.
Clostridium difficile: controversies and approaches to management.
Curr Opin Infect Dis.
2009;
22
517-524
-
9
Blondeau J M.
What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhea?.
J Antimicrob Chemother.
2009;
63
238-242
-
10
Johnson S.
Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.
J Infect.
2009;
58
403-410
-
11
Miller M, Gravel D, Mulvey M. et al .
Healthcare-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality.
Clin Infect Dis.
2010;
50
194-201
-
12
Reichardt C, Chaberny I F, Kola A. et al .
Dramatischer Anstieg von Clostridium-difficile-assoziierter Diarrhö in Deutschland.
Dtsch Med Wochenschr.
2007;
132
223-228
-
13
Robert-Koch-Institut .
Clostridium difficile: Zum Stand der Meldungen schwer verlaufender Infektionen in Deutschland.
Epidemiol Bull.
2008;
117-119
-
14
Robert-Koch-Institut .
Clostridium-difficile-assoziierte Diarrhö: Zunehmende Inzidenz in Deutschland.
Epidemiol Bull.
2008;
119
-
15
Burckhardt F, Friedrich A, Beier D, Eckmanns T.
Clostridium difficile surveillance trends, Saxony, Germany.
Emerg Infect Dis.
2008;
14
691-692
-
16
Borgmann S, Kist M, Jakobiak T. et al .
Increased number of Clostridium difficile infections and prevalence of Clostridium difficile PCR ribotype 001 in southern Germany.
Euro Surveill.
2008;
13
19 057
-
17
Cohen S H, Gerding D N, Johnson S. et al .
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA).
Infect Control Hosp Epidemiol.
2010;
31
431-455
-
18
Bauer M P, Kuijper E J, van Dissel J T.
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) treatment guidance document for Clostridium difficile infection (CDI).
Clin Microbiol Infect.
2009;
15
1067-1079
-
19
Sharp S E, Ruden L O, Pohl J C. et al .
Evaluation of the C.DIFF Quik Chek Complete assay, a new GDH & A/B toxin combination lateral flow assay for use in the rapid, simple diagnosis of Clostridium difficile disease.
J Clin Microbiol.
2010;
Apr 7 [Epub ahead of print]
-
20
Schneider T, Eckmanns T, Ignatius R. et al .
Clostridium-difficile-assoziierte Diarrhö: Ein zunehmendes klinisches Problem durch neue hochvirulente Erreger.
Dtsch Ärztebl.
2007;
104
A1588-A1594
-
21
Grünewald T, Kist M, Mutters R. et al .
Clostridium difficile.
Dtsch Med Wochenschr.
2010;
135
699-703
-
22
Best E L, Fawley W N, Parnell P, Wilcox M H.
The potential for airborne dispersal of Clostridium difficile from symptomatic patients.
Clin Infect Dis.
2010;
50
1450-1457
-
23
Sethi A K, Al-Nassir W N, Nerandzic M M. et al .
Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection.
Infect Control Hosp Epidemiol.
2010;
31
21-27
-
24
Gastmeier P, Weitzel-Kage D, Behnke M, Eckmanns T.
Surveillance of Clostridium-difficile-associated diarrhoea with the German nosocomial infection surveillance system KISS (CDAD-KISS).
Int J Antimicrob Agents.
2009;
33
S19-S23
-
25
Kutty P K, Woods C W, Sena A C. et al .
Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA.
Emerg Infect Dis.
2010;
16
197-204
-
26
Taori S K, Hall V, Poxton I R.
Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979 – 2004.
J Med Microbiol.
2010;
59
338-344
-
27
Ghantoji S S, Sail K, Lairson D R. et al .
Economic healthcare costs of Clostridium difficile infection: a systematic review.
J Hosp Infect.
2010;
74
309-318
-
28
Robert-Koch-Institut .
Clostridium-difficile-Infektionen: Übermittlungen gemäß IfSG von 01 / 2008 bis 12 / 2009.
Epidemiol Bull.
2010;
87-89
-
29
Vonberg R P, Kuijper E J, Wilcox M H. et al .
Infection control measures to limit the spread of Clostridium difficile.
Clin Microbiol Infect.
2008;
14
2-20
-
30
Abbett S K, Yokoe D S, Lipsitz S R. et al .
Proposed checklist of hospital interventions to decrease the incidence of healthcare-associated Clostridium difficile infection.
Infect Control Hosp Epidemiol.
2009;
30
1062-1069
-
31
Price J, Cheek E, Lippett S. et al .
Impact of an intervention to control Clostridium difficile infection on hospital and community onset disease; an interrupted time series analysis.
Clin Microbiol Infect.
2009;
Oct 14 [Epub ahead of print]
-
32
Pillai A, Nelson R.
Probiotics for treatment of Clostridium difficile-associated colitis in adults.
Cochrane Database Syst Rev.
2008;
CD004611
-
33
Miller M.
The fascination of probiotics for Clostridium difficile infection: Lack of evidence for prophylactic or therapeutic efficacy.
Anaerobe.
2009;
15
281-284
-
34
Tung J M, Dolovich L R, Lee C H.
Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review.
Can J Gastroenterol.
2009;
23
817-821
-
35
Janka J, O'Grady N P.
Clostridium difficile infection: current perspectives.
Curr Opin Crit Care.
2009;
15
149-153
-
36
Gash K, Brown E, Pullyblank A.
Emergency subtotal colectomy for fulminant Clostridium difficile colitis – is a surgical solution considered for all patients?.
Ann R Coll Surg Engl.
2010;
92
56-60
-
37
Wilson V, Cheek L, Satta G. et al .
Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom.
Clin Infect Dis.
2010;
May 7 [Epub ahead of print]
-
38
Musher D M, Logan N, Bressler A M. et al .
Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.
Clin Infect Dis.
2009;
48
e41-e46
-
39
Johnson S, Schriever C, Patel U. et al .
Rifaximin Redux: Treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.
Anaerobe.
2009;
15
290-291
-
40
Herpers B L, Vlaminckx B, Burkhardt O. et al .
Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.
Clin Infect Dis.
2009;
48
1732-1735
-
41
Johnson S.
Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes.
J Infect.
2009;
58
403-410
-
42
Cadena J, Thompson 3rd G R, Patterson J E. et al .
Clinical predictors and risk factors for relapsing Clostridium difficile infection.
Am J Med Sci.
2010;
339
350-355
-
43
Juang P, Skledar S J, Zgheib N J. et al .
Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea.
Am J Infect Control.
2007;
38
131-137
-
44
Lowy I, Molrine D C, Leav B A. et al .
Treatment with monoclonal antibodies against Clostridium difficile toxins.
N Engl J Med.
2010;
362
197-205
-
45
Louie T, Miller M, Donskey C. et al .
Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.
Antimicrob Agents Chemother.
2009;
53
223-228
-
46
Miller M.
Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
Expert Opin Pharmacother.
2010;
May 6 [Epub ahead of print]
-
47
Louie T J, Peppe J, Watt C K. et al .
Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.
Clin Infect Dis.
2006;
43
411-420
-
48
Weiss K.
Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer.
Int J Antimicrob Agents.
2009;
33
4-7
-
49
Baines S D, Freeman J, Wilcox M H.
Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection.
Antimicrob Agents Chemother.
2009;
53
2202-2204
-
50
Bakken J S.
Faecal bacteriotherapy for recurrent Clostridium difficile infection.
Anaerobe.
2009;
15
285-289
-
51
van Nood E, Speelman P, Kuijper E J, Keller J J.
Struggling with recurrent Clostridium difficile infections: is donor faeces the solution?.
Euro Surveill.
2009;
14
19 316
-
52
Macconnachie A A, Fox R, Kennedy D R, Seaton R A.
Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series.
QJM.
2009;
102
781-784
-
53
Hellemans R, Naegels S, Holvoet J.
Fecal transplantation for recurrent Clostridium difficile colitis, an underused treatment modality.
Acta Gastroenterol Belg.
2009;
72
269-270
Professor Dr. Winfried V. Kern
Medizinische Universitätsklinik,
Zentrum Infektiologie und Reisemedizin
Hugstetterstr. 55
79106 Freiburg
eMail: kern@if-freiburg.de
